PIN25 COST-EFFECTIVENESS ANALYSIS OF THE INTRODUCTION OF THE VARICELLA VACCINE IN COLOMBIA  by De la Hoz, F. et al.
the model is robust to a wide range of parameter estimates. CONCLUSIONS: This
analysis suggests that the use of ATVRTV in the Mexican healthcare setting is a
preferred option when compared to LPVRTV for treatment of treatment-naïve
HIV patients.
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OBJECTIVES: To examine the incremental cost-effectiveness of palivizumab vs. no
prophylaxis among 3 groups of preterm infants in a Medicaid population. Infants
were6months of age at the start of the RSV season: 1)32 weeks gestational age
(wGA); 2) High-risk (HR) 32–35 wGA ( 2 risk factors) or 3) Low-risk (LR) 32–35 wGA
(1 risk factor). METHODS: We conducted a cost-utility analysis of palivizumab
from a societal perspective based on 5 monthly doses throughout the RSV season.
Medicaid-related inputs included the background rates of RSV disease, marginal
healthcare costs within the first two years of life between infants with RSV com-
pared to controls, and the estimated public payer dollars spent for palivizumab.
The base case included recurrent wheezing (RW), which was excluded during sen-
sitivity analysis.We report the incremental cost-effectiveness ratio (ICER), morbid-
ity, and mortality between the prophylaxed and non-prophylaxed groups.
RESULTS: Prophylaxis among 32 wGA infants was dominant, with and without
RW. For HR 32-35 wGA infants, the ICER was $3,791/QALY with RW and $26,290/
QALY without RW. For LR 32-35 wGA infants, the ICER was $22,690/QALY with RW
and $231,784/QALY without RW. Compared with infants without prophylaxis, in-
fants receiving prophylaxis were projected to have fewer RSV hospitalizations
(-4214 among 32 wGA, 4734 among HR 32-35 wGA, and 1289 among LR 32-35
wGA infants) among the estimated 119,500 premature births inMedicaid in the US.
Likewise, prophylaxis was estimated to reduce the number of deaths by 42 among
32 wGA, 74 among HR 32-35wGA and 20 among LR 32-35 wGA infants.
CONCLUSIONS: Palivizumab was shown to be highly cost-effective among infants
32 wGA and HR 32-35 wGA due to Medicaid’s lower cost structure for healthcare
items and services and higher rates of disease compared to private plans. The
study was sponsored by MedImmune, LLC.
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OBJECTIVES: To perform a cost-effectiveness analysis of the introduction of the
varicella vaccine in theNational Immunization Programof Colombia.METHODS:A
decision analysis model was built to follow two cohorts from birth. One cohort had
vaccination, and the other did not. The time horizon was 30 years. The perspective
was from the third payer. Amicro-costing assessment of varicella in Colombia was
undertaken. All costs were expressed in 2008 dollars of December 31. Incremental
cost-effectiveness ratio (ICER) was the main outcomemeasure. A discount rate for
health benefits and costs of 3%was used. A sensitivity analysis wasmade to assess
assumptions uncertainty. RESULTS: Vaccination would avoid 9,415,444 consulta-
tions, 17,576 hospitalizations, and 1,144 varicella deaths. Cost per Life-Year Gained
(LYG) was US$2,527/LYG. From the third payer perspective in Colombia, varicella
costs without vaccination would be US$88 millions, and with vaccination US$35
million. The sensitivity analysis shows that the vaccination strategy is not cost-
effective if vaccination cost per dose is higher than US$15.6. In the case of a booster
dose every ten years, the vaccinationwould not be cost-effective if vaccination cost
per dose is higher than US$9.8. CONCLUSIONS: Varicella vaccination is highly
cost-effective according toWorld Health Organization criteria (less than per capita
gross domestic product). The authors recommend, weighting the budget impact,
the implementation of the varicella vaccine in Colombia.
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OBJECTIVES: The recent increase of methicillin-resistant S. aureus (MRSA) as the
leading cause of bacteremia, and subsequent infective endocarditis, has led clini-
cians to resort to alternative treatments, rather than the traditional penicillin-
based treatment strategy. Such alternatives include daptomycin,whichhas proven
to be efficacious. An economic evaluation was performed to determine the most
cost-effective alternative between daptomycin and vancomycin for the treatment
of patients with MRSA bacteremia and infective endocarditis. METHODS: A cost-
effectiveness analysis was performed from an institutional perspective (Mexican
Institute of Social Security, IMSS). Vancomycin is currently the treatment of choice
for infective endocarditis within the treatment guidelines; daptomycin is regarded
as an alternative treatment. Effectiveness and safety data was taken from pub-
lished literature; effectiveness parameters included clinical and bacteriological
cure, and safety parameters included drug-related adverse events. Resource use
data was obtained from the institution; total direct costs of hospitalization and
treatment were considered. The source of the unit costs was the institution, cur-
rent for 2010. All costs are expressed in local currency (Mexican Pesos, MXP). The
time horizon was less than 1 year; no discount rate was used. A decision tree was
built with three possible outcomes considered: success or failure to treatment, and
death. A probabilistic sensitivity analysis was performed through a Monte Carlo
simulation with 100,000 iterations to confirm the robustness of the model.
RESULTS: The results show a cost/effectiveness ratio of $371,813.80 MXP for dap-
tomycin compared to $466,229.23MXP for vancomycin,making daptomycin amore
cost-effective alternative (dominant) for the treatment of bacteremia and infective
endocarditis. CONCLUSIONS: From an institutional perspective in Mexico, dapto-
mycin is a more cost-effective (dominant) alternative than vancomycin for the
treatment of bacteremia and infective endocarditis in patients with MRSA infec-
tion.
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OBJECTIVES: The loss of vaccine-induced immunity to pertussis over ten years
after administered increment the burden of pertussis-related disease. To diminish
the burden of pertussis-related disease on children under-5 years we propose a
cost-effectiveness analysis of the introduction of pertussis vaccine in Colombian
adolescents. METHODS: Two cohorts (with vaccinated and unvaccinated adoles-
cents) of childrenwere followed from birth to 5 years (both vaccinatedwith current
scheme: 2-4-6-18 months and 5 years with DTwP). A decision model was used to
estimate the burden of pertussis-related disease. The cost of pertussis was taken
from a previous study. A government perspective was used. Vaccine administra-
tion cost plus vaccine price were assumed between US$5-US$12 per dose. Adoles-
cent vaccination coveragewasassumed tobe 70%.Adeterministic sensitivity analysis
was performed. Costs were US dollars from 2008. RESULTS: Without adolescents
vaccination, the current scheme reduce 93% pertussis cases (from 102,196 to 6,912),
83% deaths (from 408 to 55), and 93% DALYs (18,189 to 1,233). With adolescent
vaccination, cases would reduce from 6,912 to 4,838, deaths from 408 to 39, and
DALYs from 1,233 to 860, in the current scenario. Total pertussis costs without
adolescent vaccination is US$737,186, andwith vaccination US$516,030. Incremen-
tal Cost-Effectiveness Ratiowith a vaccination coverage of 70%would go from4,188
(vaccination cost per dose: US$5) to 10,331 (vaccination cost per dose: US$12).
CONCLUSIONS: This is the first study in a developing country that assesses per-
tussis vaccination in adolescent. Pertussis adolescent vaccination was cost-effec-
tive in Colombia, according to World Health Organization criteria (less than three
times the per-capita Gross Domestic Product). The investigators recommend ado-
lescents pertussis vaccination in Colombia.
PIN28
ESTIMATED HEALTH AND ECONOMIC IMPACT OF QUADRIVALENT HPV TYPES
6, 11, 16, 18 VACCINE IN BRAZIL USING A TRANSMISSION DYNAMIC MODEL
Singhal PK1, Tannus G2, Fonseca M2, Kawai K3, Dasbach E4
1Merck & Co., Inc., West Point, PA, USA, 2Axia.Bio, São Paulo, Brazil, 3Merck & Co., Inc./Temple
University, West Point, PA, USA, 4Merck Research Laboratories, North Wales, PA, USA
OBJECTIVES: The quadrivalent (6,11,16,18) HPV vaccine has been approved in Bra-
zil for prevention of cervical cancer, vulvar/vaginal pre-cancers, and genital warts
in women age 9 to 26 years. We assessed the health and economic impact of the
quadrivalent (6,11,16,18) HPV vaccine from the healthcare system perspective in
Brazil.METHODS: A publishedmathematical model of the transmission dynamics
of HPV infection and disease was adapted for Brazil. Model inputs were used from
Brazil or the Latin/America region when available; otherwise, the default values in
the original model were used. Maintaining current cervical cancer screening prac-
tices in Brazil, we evaluated two strategies: routine vaccination of females by age 12
(S1), and S1 combined with a temporary (5 years) female catch-up program for age
12–24 years (S2). The vaccine coverage rates were 85% for the routine and 50% for
the catch-up vaccination programs. RESULTS: The most effective strategy was S2.
Comparing S2 to no vaccination, we estimated the cumulative percent reduction in
incident HPV 6/11/16/18-related genital warts-female, genital warts-male, cervical
intraepithelial neoplasia (CIN) grade 1, CIN 2/3, and cervical cancer cases would be
81%, 57%, 70%, 72%, and 59%, respectively over 100 years. The cost-effectiveness
ratios were Brazil Reals 1,203 (US$ 699) per quality-adjusted life years (QALY)
gained for S1 compared with no vaccination, and Brazil Reals 1,522 (US$ 885) per
QALY gained for S2 compared with S1. CONCLUSIONS: In Brazil, vaccination of
females age 12–24 years with a quadrivalent (6,11,16,18) HPV vaccine can reduce
the incidence of cervical cancer, CIN, and genital warts at a cost per QALY ratio
within the range typically regarded by the World Health Organization as cost-
effective.
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OBJECTIVES: The incidence of skin and soft tissue infections (SSTI) has augmented
recently in Mexico, mainly due to increases in vancomycin-resistant pathogens
and immunocompromised patients. New antibiotics, such as daptomycin, have
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